Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBP6
The NM_001122955.4(BSCL2):c.1100C>T(p.Pro367Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000672 in 1,613,522 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
BSCL2 (HGNC:15832): (BSCL2 lipid droplet biogenesis associated, seipin) This gene encodes the multi-pass transmembrane protein protein seipin. This protein localizes to the endoplasmic reticulum and may be important for lipid droplet morphology. Mutations in this gene have been associated with congenital generalized lipodystrophy type 2 or Berardinelli-Seip syndrome, a rare autosomal recessive disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. Naturally occurring read-through transcription occurs between this locus and the neighboring locus HNRNPUL2 (heterogeneous nuclear ribonucleoprotein U-like 2).[provided by RefSeq, Mar 2011]
Verdict is Likely_benign. Variant got -3 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.029188484).
BP6
Variant 11-62690840-G-A is Benign according to our data. Variant chr11-62690840-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 199176.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=6, Uncertain_significance=6}. Variant chr11-62690840-G-A is described in Lovd as [Likely_benign].
Uncertain significance, criteria provided, single submitter
clinical testing
Eurofins Ntd Llc (ga)
Sep 02, 2015
- -
Likely benign, criteria provided, single submitter
clinical testing
Athena Diagnostics
Feb 04, 2020
- -
Uncertain significance, criteria provided, single submitter
clinical testing
GeneDx
Aug 18, 2023
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 32041611) -
Uncertain significance, criteria provided, single submitter
clinical testing
CeGaT Center for Human Genetics Tuebingen
Nov 01, 2022
- -
Uncertain significance, criteria provided, single submitter
clinical testing
Revvity Omics, Revvity
Nov 13, 2020
- -
Uncertain significance, criteria provided, single submitter
clinical testing
Mayo Clinic Laboratories, Mayo Clinic
Sep 22, 2022
BP4 -
Hereditary spastic paraplegia Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
Genome Diagnostics Laboratory, The Hospital for Sick Children
Feb 01, 2019
- -
not specified Benign:1
Likely benign, criteria provided, single submitter
clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Apr 26, 2019
- -
Neurologic Disorders/Seipinopathy Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Illumina Laboratory Services, Illumina
Jun 14, 2016
- -
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Mar 17, 2023
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Charcot-Marie-Tooth disease type 2 Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Labcorp Genetics (formerly Invitae), Labcorp
Jan 17, 2024
- -
Congenital generalized lipodystrophy Benign:1
Likely benign, criteria provided, single submitter